Over the five years to 2015, the Cold Sore Medication Manufacturing industry has enjoyed slow but stable growth. Falling unemployment, rising per capita disposable income and the expansion of healthcare coverage have made consumers better able to afford industry products. Meanwhile, because the elderly are more susceptible to cold sore outbreaks, the aging of the population has further boosted demand for industry medications. However, since the expirations of patents on some of the industry's name-brand medications, competition from discount generics has eroded revenue. Still, favorable economic trends will make consumers less sensitive to price and more willing to purchase name-brand products in the coming five years, which will enable faster industry growth than in the previous period.
This industry develops and produces over-the-counter (OTC) and prescription treatments for cold sores, which are inflamed blisters in or near the mouth, caused by infection from the herpes simplex virus.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.